Skip to main content

Table 2 Adverse events (n = 71) during a median follow up of 36 months of TG therapy

From: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom

  Grade 1 (mild)
(n = 59)
Grade 2 (moderate)
(n = 9)
Grade 3 (severe)
(n = 3)
General, neurological and psychological Flu-like symptoms 7   
Blood, lymphatic and vascular disorders Bone marrow suppression 12 Bone-marrow suppression 2  
Musculoskeletal and skin disorders Alopecia 5   
Rash 9
Arthralgia/myalgia 8
Hepatobiliary disorders DILI 9 DILI 3 Portal hypertension 2
Gastrointestinal disorders Nausea 5 Diarrhea 1 Pancreatitis 1
Abdominal pain 4
Infections and infestations   EBV infection 1 Herpetic eye infection 1
Neoplasm benign and malign   Melanoma 1 Diffuse large B-cell lymphoma 1
Recurrent breast cancer 1
  1. DILI Drug-induced liver injury, DILI grade 1 is defined as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 1.25 and ≤ 3 upper limit of normal (ULN) and total bilirubin > 1.25 and ≤ 2 ULN, grade 2 is defined as ALT and AST > 3 and ≤ 5 ULN and total bilirubin > 2 and ≤ 3 ULN. Bone marrow suppression: grade 1 < =25% reduction from normal cellularity for age, grade 2: > 25 - < 50% reduction from normal cellularity for age, grade 3: > 50 - < =75% reduction cellularity from normal for age